Company: OWL Metabolomics (in Partnership with Cerba Research)
Job title: Chief Executive Officer
Pablo Ortiz became MD by Universidad Autonoma of Madrid (1972-1978) where also made his PhD (1984-1990) on liver metabolism.
Extensive training in management R+D projects in drug develoment and clinical trials in over 25 years (1979-2004) in Boehringer Ingelheim.
From June 2004 till Nov 2012 he was CEO at Digna Biotech, a spin-off of University of Navarra reaching with 4 products till Phase II in this period. He joined OWL in January 2013 as a senior consultant and in June 2014 as CEO to develop the first non invasive diagnostic of NASH based on metabolomics.
He has published 30 papers in international journals..